Screener
Monte Rosa Therapeutics, Inc. GLUE Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $90.1M+29.8% | $159.86M+104% | $129.88M-42.1% | $208.34M+65.9% | $69.43M-36.2% | ||
| $631.41M+111% | $677.55M+104% | $393.19M+4.2% | $401.82M+60.0% | $299.47M+7.8% | ||
| $29.93M+3.0% | $28.41M-3.2% | $25.99M-11.9% | $27.6M-12.2% | $29.05M-12.6% | ||
| $691.16M+92.2% | $736.43M+87.3% | $448.66M+2.3% | $459.84M+45.9% | $359.59M+4.5% | ||
| $7.15M+28.1% | $7.9M+21.7% | $3.55M-79.4% | $14.51M+265% | $5.58M-13.8% | ||
| $105.62M+1,211% | $103.64M+515% | $111.33M+589% | $111.89M+346% | $8.06M-76.0% | ||
| $59.66M+42.5% | $71.04M+20.0% | $64.21M-59.1% | $61.44M+47.6% | $41.85M-1.2% | ||
| $203.88M+123% | $214.51M+81.7% | $215.6M-0.1% | $214M+95.2% | $91.51M-23.4% | ||
| $9K+50.0% | $8K+33.3% | $7K+16.7% | $6K0.0% | $6K0.0% | ||
| -$565.11M-39.9% | -$521.72M-33.2% | -$477.21M-8.8% | -$431.08M+4.6% | -$404M+5.6% | ||
| $487.28M+81.8% | $521.92M+89.7% | $233.06M+4.5% | $245.84M+19.7% | $268.08M+19.3% | ||
| $691.16M+92.2% | $736.43M+87.3% | $448.66M+2.3% | $459.84M+45.9% | $359.59M+4.5% |
FAQ
- What are Monte Rosa Therapeutics, Inc.'s total assets?
- Monte Rosa Therapeutics, Inc. (GLUE) holds $691.2M in total assets, up 92.2% year over year.
- How much debt does Monte Rosa Therapeutics, Inc. have?
- Monte Rosa Therapeutics, Inc. carries $38.0M in total debt against $487.3M of shareholders' equity, a debt-to-equity ratio of 0.08.
- How much cash does Monte Rosa Therapeutics, Inc. have?
- Monte Rosa Therapeutics, Inc. holds $90.1M in cash and equivalents.
- Can Monte Rosa Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 10.58 — current assets exceed current liabilities.
- Where does Monte Rosa Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
